These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32670504)

  • 1. Turning genome-wide association study findings into opportunities for drug repositioning.
    Lau A; So HC
    Comput Struct Biotechnol J; 2020; 18():1639-1650. PubMed ID: 32670504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
    Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures.
    Emon MA; Domingo-Fernández D; Hoyt CT; Hofmann-Apitius M
    BMC Bioinformatics; 2020 Jun; 21(1):231. PubMed ID: 32503412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connecting genetics and gene expression data for target prioritisation and drug repositioning.
    Ferrero E; Agarwal P
    BioData Min; 2018; 11():7. PubMed ID: 29881461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating GWAS findings into therapies for depression and anxiety disorders: gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning.
    So HC; Chau CK; Lau A; Wong SY; Zhao K
    Psychol Med; 2019 Dec; 49(16):2692-2708. PubMed ID: 30569882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network mirroring for drug repositioning.
    Park S; Lee DG; Shin H
    BMC Med Inform Decis Mak; 2017 May; 17(Suppl 1):55. PubMed ID: 28539121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry.
    So HC; Chau CK; Chiu WT; Ho KS; Lo CP; Yim SH; Sham PC
    Nat Neurosci; 2017 Oct; 20(10):1342-1349. PubMed ID: 28805813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.
    Nabirotchkin S; Bouaziz J; Glibert F; Mandel J; Foucquier J; Hajj R; Callizot N; Cholet N; Guedj M; Cohen D
    J Alzheimers Dis; 2022; 88(4):1585-1603. PubMed ID: 35811522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational drug repurposing for inflammatory bowel disease using genetic information.
    Grenier L; Hu P
    Comput Struct Biotechnol J; 2019; 17():127-135. PubMed ID: 30728920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mining integrated semantic networks for drug repositioning opportunities.
    Mullen J; Cockell SJ; Tipney H; Woollard PM; Wipat A
    PeerJ; 2016; 4():e1558. PubMed ID: 26844016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Repositioning for Schizophrenia and Depression/Anxiety Disorders: A Machine Learning Approach Leveraging Expression Data.
    Zhao K; So HC
    IEEE J Biomed Health Inform; 2019 May; 23(3):1304-1315. PubMed ID: 30010603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities.
    Jhamb D; Magid-Slav M; Hurle MR; Agarwal P
    Drug Discov Today; 2019 Jun; 24(6):1232-1236. PubMed ID: 30935985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs.
    Parisi D; Adasme MF; Sveshnikova A; Bolz SN; Moreau Y; Schroeder M
    Comput Struct Biotechnol J; 2020; 18():1043-1055. PubMed ID: 32419905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Learning Opportunities for Drug Repositioning via GWAS and PheWAS Findings.
    Yin W; Gao C; Xu Y; Li B; Ruderfer DM; Chen Y
    AMIA Jt Summits Transl Sci Proc; 2018; 2017():237-246. PubMed ID: 29888080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing the Promise of Drug Repositioning through Genetics.
    Pritchard JE; O'Mara TA; Glubb DM
    Front Pharmacol; 2017; 8():896. PubMed ID: 29270124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions.
    Jarada TN; Rokne JG; Alhajj R
    J Cheminform; 2020 Jul; 12(1):46. PubMed ID: 33431024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutics for coronary artery disease from genome-wide association study data.
    Grover MP; Ballouz S; Mohanasundaram KA; George RA; Goscinski A; Crowley TM; Sherman CD; Wouters MA
    BMC Med Genomics; 2015; 8 Suppl 2(Suppl 2):S1. PubMed ID: 26044129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug repositioning for diabetes based on 'omics' data mining.
    Zhang M; Luo H; Xi Z; Rogaeva E
    PLoS One; 2015; 10(5):e0126082. PubMed ID: 25946000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translating GWAS Findings to Inform Drug Repositioning Strategies for COVID-19 Treatment.
    Tsai MJ; Jeong S; Yu F; Chen TF; Li PH; Juan HF; Huang JH; Hsu YH
    Res Sq; 2023 Oct; ():. PubMed ID: 37886583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.